Chronic News and Research

RSS

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

16 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Drug abuse appears to foster brain changes that resemble schizophrenia

Teens who were heavy marijuana users -- smoking it daily for about three years -- had abnormal changes in their brain structures related to working memory and performed poorly on memory tasks, reports a new Northwestern Medicine- study.

16 Dec 2013

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

In 2012, about 58,500 paid, regulated long-term care services providers served about 8 million people in the United States. Long-term care services were provided by 4,800 adult day services centers, 12,200 home health agencies, 3,700 hospices, 15,700 nursing homes, and 22,200 assisted living and similar residential care communities. Each day in 2012, there were 273,200 participants enrolled in adult day services centers, 1,383,700 residents in nursing homes, and 713,300 residents in residential care communities; in 2011, about 4,742,500 patients received services from home health agencies, and 1,244,500 patients received services from hospices. Provider sectors differed in ownership, and average size and supply varied by region (Harris-Kojetin et al., 12/12).

16 Dec 2013

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.

16 Dec 2013

Diabetes most common among older men and those living in the South

About 8.8 percent of the privately insured population in 2012 had diabetes or was diagnosed as being at high risk for diabetes, up from 8.3 percent in 2011, but the rates of disease varied depending on age, gender and region of the country, says a new report from HCCI. In 2012, over one quarter of men between the ages of 55-64 and nearly one in 10 Southerners had diabetes or were at risk for diabetes.

16 Dec 2013

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

Today, the International Osteoporosis Foundation recognized the outstanding work of five young researchers from China, Chinese Taipei, Hong Kong, Malaysia and Pakistan.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

New UCSF-led study links obesity to development of chronic kidney disease

A new UCSF-led study of nearly 3,000 individuals links obesity to the development of kidney disease. The work also shows that, when properly measured, declines in kidney function are detectable long before the emergence of other obesity-related diseases such as diabetes and high blood pressure.

14 Dec 2013

Savient gets bankruptcy court approval to sell all assets to Crealta

Savient Pharmaceuticals, Inc. announced that it has received approval from the U.S. Bankruptcy Court for the District of Delaware to sell substantially all of the assets of Savient, including all KRYSTEXXA assets, to Crealta Pharmaceuticals LLC.

13 Dec 2013

CEO Cancer Gold Standard accreditation awarded to Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc., the largest U.S. subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT, is leading by example when it comes to promoting workplace wellness and encouraging healthier behavior.

13 Dec 2013

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

New treatment options for diabetic wound healing in cornea and skin

Diabetes Mellitus (DM), a metabolic disorder that affects nearly 170 million people worldwide, is characterized by chronic hyperglycemia that disrupts carbohydrate fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. DM can cause long-term damage, dysfunction and even failure of various organs.

13 Dec 2013

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis.

13 Dec 2013

Exercise may slow kidney function decline in kidney disease patients

Increased physical activity may slow kidney function decline in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings suggest that exercise could have a powerful effect on maintaining patients' health.

13 Dec 2013

Chronic News and Research

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Drug abuse appears to foster brain changes that resemble schizophrenia

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Diabetes most common among older men and those living in the South

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

Study could lead towards a personalised medicine for chemoresistant lymphomata

New UCSF-led study links obesity to development of chronic kidney disease

Savient gets bankruptcy court approval to sell all assets to Crealta

CEO Cancer Gold Standard accreditation awarded to Boehringer Ingelheim Pharmaceuticals

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

New treatment options for diabetic wound healing in cornea and skin

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Exercise may slow kidney function decline in kidney disease patients

Study: Immune cells outside the brain may regulate propensity to develop depression

Airway alterations present even in young smokers without COPD

Study shows that age and sleep deprivation induce cellular stress in pancreas

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News